Exact Sciences Corporation has announced that its Oncodetect™ molecular residual disease $(MRD.AU)$ test has received Medicare coverage through the Centers for Medicare & Medicaid Services' $(CMS)$ Molecular Diagnostic Services Program (MolDX). This coverage is for serial use in patients with stage II, III, and resectable stage IV colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period. This approval is a significant milestone in Exact Sciences' mission to enhance cancer treatment through earlier detection and personalized care. The Oncodetect test, which tracks up to 200 ctDNA variants, has demonstrated its prognostic power in robust clinical validation studies and can detect signs of cancer recurrence up to two years earlier than imaging alone. This development underscores the clinical value of the MRD test and reinforces Exact Sciences' leadership in advancing oncology diagnostic tools.